title: The 719Arg variant of KIF6 and cardiovascular outcomes in statin-treated, stable coronary patients of the treating to new targets and incremental decrease in end points through aggressive lipid-lowering prospective studies.
abstract: BACKGROUND
  Carriers of the KIF6 719Arg variant may be at increased risk for CVD and may benefit more from statin therapy, in terms of CVD risk reduction, than noncarriers. Our objective was to investigate whether carriers of the KIF6 719Arg genetic variant (rs20455) are at increased cardiovascular risk and obtain more benefit from high-dose statin therapy than do noncarriers.
  
  
  RESULTS
  We used an adjusted Cox proportional hazard model to assess the hazard ratio (HR) for the reduction of major cardiovascular events by 80 mg/d atorvastatin over 10 mg/d atorvastatin in 4599 patients of the Treating to New Targets (TNT) study and by 80 mg/d atorvastatin over 20-40 mg/d simvastatin in 6541 patients of the Incremental Decrease in End Points Through Aggressive Lipid-Lowering (IDEAL) study. A total of 381 and 648 patients had a cardiovascular event during follow-up in TNT and IDEAL, respectively. Heterozygotes and homozygotes for the minor allele were not at increased risk compared with noncarriers. In TNT, for noncarriers of the 719Arg allele, the HR for high- versus low-dose atorvastatin was 0.81 (95% confidence interval, 0.59-1.11). In carriers of 1 or 2 minor alleles, the HR was 0.85 (0.66-1.11) and carriers of 2 copies of the minor allele obtained a significant risk reduction (HR: 0.44, 95% confidence interval, 0.23-0.84). In IDEAL, the respective HRs were 0.85 (0.67-1.10), 0.88 (0.62-1.07) and 0.91 (0.58-1.43). The interaction term for carrier status by treatment was also nonsignificant (P=0.810 in TNT and P=0.909 in IDEAL).
  
  
  CONCLUSIONS
  In these 2 large, randomized clinical trials, carriers of the KIF6 719Arg allele were not at increased cardiovascular risk and did not obtain consistent cardiovascular benefit from high-dose statin therapy compared with noncarriers.
authors.affiliation: Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands.
authors.forename: Benoit J
authors.initials: BJ
authors.lastname: Arsenault
authors.forename: S Matthijs
authors.initials: SM
authors.lastname: Boekholdt
authors.forename: G Kees
authors.initials: GK
authors.lastname: Hovingh
authors.forename: Craig L
authors.initials: CL
authors.lastname: Hyde
authors.forename: David A
authors.initials: DA
authors.lastname: DeMicco
authors.forename: Aurobindo
authors.initials: A
authors.lastname: Chatterjee
authors.forename: Philip
authors.initials: P
authors.lastname: Barter
authors.forename: Prakash
authors.initials: P
authors.lastname: Deedwania
authors.forename: David D
authors.initials: DD
authors.lastname: Waters
authors.forename: John C
authors.initials: JC
authors.lastname: LaRosa
authors.forename: Terje R
authors.initials: TR
authors.lastname: Pedersen
authors.forename: John J P
authors.initials: JJ
authors.lastname: Kastelein
mesh_terms: D000368:Aged; D000483:Alleles; D000069059:Atorvastatin; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D008078:Cholesterol, LDL / Q000097:blood; D005260:Female; D005500:Follow-Up Studies; D005838:Genotype; D006538:Heptanoic Acids / Q000627:therapeutic use*; D006579:Heterozygote; D006720:Homozygote; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D016547:Kinesins / Q000235:genetics* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D016016:Proportional Hazards Models; D011446:Prospective Studies; D011758:Pyrroles / Q000627:therapeutic use*; D012307:Risk Factors; D019821:Simvastatin / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D008078:Cholesterol, LDL; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011758:Pyrroles; D000069059:Atorvastatin; D019821:Simvastatin; C526774:KIF6 protein, human; D016547:Kinesins